Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden

Neurobiol Aging. 2013 Dec;34(12):2835-42. doi: 10.1016/j.neurobiolaging.2013.05.030. Epub 2013 Jul 13.

Abstract

The development of amyloid imaging compounds has allowed in vivo imaging of amyloid deposition. In this study, we examined the spatial patterns of amyloid deposition throughout the brain using Pittsburgh Compound Blue ((11)C-PiB) positron emission tomography data from the Baltimore Longitudinal Study of Aging. We used a new methodology that allowed us to approximate spatial patterns of the temporal progression of amyloid plaque deposition from cross-sectional data. Our results are consistent with patterns of progression known from autopsy studies, with frontal and precuneus regions affected early and occipital and sensorimotor cortices affected later in disease progression--here, disease progression means lower-to-higher total amyloid burden. Furthermore, we divided participants into subgroups based on longitudinal change in memory performance, and demonstrated significantly different spatial patterns of the estimated progression of amyloid deposition between these subgroups. Our results indicate that the spatial pattern of amyloid deposition is related to cognitive performance and may be more informative than a biomarker reflecting total amyloid burden, the use of which is the current practice. This finding has broad implications for our understanding of the relationship between cognitive decline/resilience and amyloid deposition, as well as for the use of amyloid imaging as a biomarker in research and clinical applications.

Keywords: Amyloid; CVLT; Cognition; PET; PiB.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amyloidogenic Proteins / metabolism*
  • Aniline Compounds
  • Biomarkers / metabolism
  • Carbon Radioisotopes
  • Cerebral Cortex / diagnostic imaging*
  • Cerebral Cortex / metabolism*
  • Cognition Disorders / diagnostic imaging*
  • Cognition Disorders / metabolism*
  • Cognition Disorders / psychology
  • Disease Progression
  • Female
  • Humans
  • Male
  • Memory / physiology*
  • Molecular Imaging / methods*
  • Radiopharmaceuticals
  • Thiazoles
  • Tomography, Emission-Computed

Substances

  • 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
  • Amyloidogenic Proteins
  • Aniline Compounds
  • Biomarkers
  • Carbon Radioisotopes
  • Radiopharmaceuticals
  • Thiazoles